 David Ecker
Concepts (583)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spectrometry, Mass, Electrospray Ionization | 46 | 2019 | 176 | 4.170 |
Why?
| | Polymerase Chain Reaction | 50 | 2020 | 1046 | 3.170 |
Why?
| | Molecular Diagnostic Techniques | 11 | 2016 | 104 | 1.410 |
Why?
| | Biosensing Techniques | 5 | 2014 | 142 | 1.370 |
Why?
| | Bacteria | 13 | 2016 | 769 | 1.060 |
Why?
| | Microbiological Techniques | 6 | 2013 | 30 | 0.980 |
Why?
| | DNA, Bacterial | 19 | 2016 | 320 | 0.940 |
Why?
| | Lyme Disease | 6 | 2020 | 58 | 0.920 |
Why?
| | Ixodes | 5 | 2017 | 12 | 0.800 |
Why?
| | Biohazard Release | 1 | 2023 | 1 | 0.790 |
Why?
| | Communicable Diseases, Emerging | 4 | 2008 | 39 | 0.780 |
Why?
| | Biological Warfare Agents | 2 | 2013 | 3 | 0.770 |
Why?
| | Disease Outbreaks | 5 | 2023 | 420 | 0.750 |
Why?
| | Viruses | 6 | 2012 | 166 | 0.720 |
Why?
| | Genotype | 22 | 2019 | 1875 | 0.710 |
Why?
| | Blood | 5 | 2016 | 107 | 0.690 |
Why?
| | Bacterial Typing Techniques | 12 | 2013 | 40 | 0.650 |
Why?
| | Sensitivity and Specificity | 19 | 2023 | 2017 | 0.630 |
Why?
| | Borrelia burgdorferi | 5 | 2020 | 21 | 0.630 |
Why?
| | Clinical Competence | 2 | 2018 | 1260 | 0.610 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 8 | 2013 | 980 | 0.600 |
Why?
| | Bacteremia | 6 | 2015 | 222 | 0.600 |
Why?
| | Drug Design | 5 | 2008 | 177 | 0.580 |
Why?
| | Licensure, Medical | 1 | 2018 | 17 | 0.550 |
Why?
| | Physician Executives | 1 | 2018 | 30 | 0.530 |
Why?
| | Delivery of Health Care | 1 | 2024 | 951 | 0.500 |
Why?
| | Mass Spectrometry | 11 | 2014 | 728 | 0.490 |
Why?
| | Escherichia coli | 14 | 2015 | 836 | 0.490 |
Why?
| | Base Sequence | 30 | 2012 | 2175 | 0.480 |
Why?
| | Population Surveillance | 3 | 2009 | 486 | 0.460 |
Why?
| | Anaplasmataceae | 1 | 2015 | 1 | 0.460 |
Why?
| | DNA Primers | 14 | 2012 | 505 | 0.430 |
Why?
| | Educational Measurement | 1 | 2018 | 332 | 0.430 |
Why?
| | Virus Diseases | 5 | 2014 | 218 | 0.430 |
Why?
| | Hospitals | 2 | 2023 | 740 | 0.420 |
Why?
| | DNA, Fungal | 3 | 2014 | 77 | 0.410 |
Why?
| | Bacteriological Techniques | 6 | 2016 | 66 | 0.410 |
Why?
| | Candida | 2 | 2013 | 46 | 0.410 |
Why?
| | Civil Defense | 1 | 2013 | 20 | 0.400 |
Why?
| | Communicable Diseases | 2 | 2013 | 166 | 0.390 |
Why?
| | Acinetobacter baumannii | 6 | 2012 | 26 | 0.380 |
Why?
| | RNA, Viral | 8 | 2010 | 695 | 0.380 |
Why?
| | Biodiversity | 1 | 2015 | 315 | 0.370 |
Why?
| | Molecular Sequence Data | 25 | 2014 | 2886 | 0.360 |
Why?
| | Oligodeoxyribonucleotides | 5 | 1998 | 141 | 0.340 |
Why?
| | Thionucleotides | 5 | 1998 | 35 | 0.340 |
Why?
| | Point-of-Care Systems | 1 | 2013 | 189 | 0.340 |
Why?
| | Borrelia | 5 | 2014 | 9 | 0.330 |
Why?
| | Influenza A virus | 3 | 2011 | 119 | 0.320 |
Why?
| | Respiratory Tract Infections | 4 | 2011 | 399 | 0.320 |
Why?
| | Acinetobacter Infections | 6 | 2012 | 15 | 0.320 |
Why?
| | Fungemia | 1 | 2010 | 10 | 0.320 |
Why?
| | Molecular Epidemiology | 3 | 2010 | 74 | 0.310 |
Why?
| | Humans | 86 | 2024 | 147293 | 0.310 |
Why?
| | Computer Simulation | 6 | 2023 | 1018 | 0.300 |
Why?
| | Anti-Bacterial Agents | 7 | 2019 | 1940 | 0.300 |
Why?
| | Cross Infection | 3 | 2010 | 261 | 0.300 |
Why?
| | Rickettsia | 4 | 2017 | 11 | 0.300 |
Why?
| | Acinetobacter | 4 | 2013 | 16 | 0.290 |
Why?
| | Genetics, Microbial | 1 | 2009 | 10 | 0.290 |
Why?
| | Biological Products | 2 | 2009 | 258 | 0.270 |
Why?
| | Fungi | 6 | 2013 | 122 | 0.270 |
Why?
| | Adenoviridae | 2 | 2011 | 199 | 0.270 |
Why?
| | Ubiquitins | 9 | 1994 | 31 | 0.270 |
Why?
| | Drug Discovery | 1 | 2009 | 153 | 0.260 |
Why?
| | Adenoviridae Infections | 1 | 2007 | 20 | 0.260 |
Why?
| | Environmental Microbiology | 1 | 2007 | 47 | 0.260 |
Why?
| | Oligonucleotides, Antisense | 6 | 1993 | 122 | 0.260 |
Why?
| | Culex | 1 | 2007 | 14 | 0.260 |
Why?
| | Staphylococcus aureus | 7 | 2014 | 458 | 0.260 |
Why?
| | Alphavirus | 1 | 2007 | 22 | 0.260 |
Why?
| | Nucleic Acid Conformation | 12 | 2005 | 726 | 0.260 |
Why?
| | Bacterial Infections | 5 | 2014 | 247 | 0.250 |
Why?
| | Bioterrorism | 3 | 2008 | 31 | 0.250 |
Why?
| | HIV-1 | 6 | 2002 | 917 | 0.250 |
Why?
| | Aedes | 1 | 2007 | 67 | 0.240 |
Why?
| | Antibody Formation | 1 | 2008 | 288 | 0.240 |
Why?
| | Base Composition | 6 | 2012 | 82 | 0.240 |
Why?
| | Microbial Sensitivity Tests | 6 | 2015 | 367 | 0.240 |
Why?
| | Animals | 37 | 2017 | 38410 | 0.230 |
Why?
| | Sequence Alignment | 3 | 2010 | 362 | 0.230 |
Why?
| | Klebsiella pneumoniae | 3 | 2015 | 48 | 0.230 |
Why?
| | 5' Untranslated Regions | 2 | 2004 | 60 | 0.220 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2023 | 539 | 0.220 |
Why?
| | Coronaviridae Infections | 1 | 2005 | 3 | 0.220 |
Why?
| | Coronaviridae | 1 | 2005 | 4 | 0.220 |
Why?
| | DNA, Viral | 6 | 2014 | 357 | 0.220 |
Why?
| | Sentinel Surveillance | 1 | 2005 | 48 | 0.220 |
Why?
| | RNA | 10 | 2010 | 916 | 0.220 |
Why?
| | Chromosome Mapping | 2 | 2004 | 512 | 0.210 |
Why?
| | Tick-Borne Diseases | 3 | 2020 | 11 | 0.210 |
Why?
| | Antiviral Agents | 4 | 1994 | 776 | 0.210 |
Why?
| | Oligonucleotides | 4 | 1997 | 154 | 0.200 |
Why?
| | Candidemia | 2 | 2014 | 16 | 0.200 |
Why?
| | Databases, Factual | 3 | 2008 | 1504 | 0.200 |
Why?
| | Virulence Factors | 1 | 2005 | 175 | 0.200 |
Why?
| | Drug Resistance, Bacterial | 5 | 2013 | 185 | 0.200 |
Why?
| | beta-Lactam Resistance | 2 | 2015 | 10 | 0.190 |
Why?
| | Symbiosis | 2 | 2015 | 73 | 0.190 |
Why?
| | Pharmacology | 1 | 2003 | 10 | 0.190 |
Why?
| | Embryonic Development | 1 | 2004 | 125 | 0.190 |
Why?
| | Gene Products, rev | 1 | 2002 | 6 | 0.190 |
Why?
| | Mycoses | 4 | 2014 | 88 | 0.190 |
Why?
| | Genes, Bacterial | 5 | 2013 | 152 | 0.190 |
Why?
| | Lentivirus | 1 | 2002 | 62 | 0.180 |
Why?
| | Response Elements | 1 | 2002 | 86 | 0.180 |
Why?
| | Saccharomyces cerevisiae | 10 | 1994 | 584 | 0.180 |
Why?
| | Faculty | 1 | 2023 | 150 | 0.180 |
Why?
| | Schools, Medical | 1 | 2023 | 159 | 0.180 |
Why?
| | Virology | 2 | 2013 | 37 | 0.180 |
Why?
| | Staphylococcal Infections | 3 | 2014 | 395 | 0.180 |
Why?
| | Sequence Analysis, RNA | 1 | 2004 | 443 | 0.180 |
Why?
| | Transcription, Genetic | 5 | 2001 | 1456 | 0.180 |
Why?
| | Oligoribonucleotides | 2 | 1992 | 53 | 0.180 |
Why?
| | Algorithms | 5 | 2011 | 1868 | 0.170 |
Why?
| | Flaviviridae | 1 | 2001 | 10 | 0.170 |
Why?
| | Central Nervous System Infections | 2 | 2012 | 35 | 0.170 |
Why?
| | Health Equity | 1 | 2024 | 137 | 0.170 |
Why?
| | Borrelia burgdorferi Group | 1 | 2020 | 7 | 0.170 |
Why?
| | Gene Expression Regulation | 7 | 2004 | 2625 | 0.160 |
Why?
| | Babesia | 2 | 2017 | 3 | 0.160 |
Why?
| | Anaplasma phagocytophilum | 2 | 2017 | 3 | 0.160 |
Why?
| | Tuberculosis, Multidrug-Resistant | 2 | 2011 | 47 | 0.160 |
Why?
| | HIV | 2 | 1992 | 251 | 0.160 |
Why?
| | Antineoplastic Agents | 2 | 2009 | 2231 | 0.160 |
Why?
| | Behavior, Animal | 1 | 2004 | 530 | 0.160 |
Why?
| | HIV-2 | 2 | 2002 | 18 | 0.160 |
Why?
| | Benzoates | 1 | 1999 | 51 | 0.150 |
Why?
| | Genetic Techniques | 2 | 2005 | 66 | 0.150 |
Why?
| | California | 2 | 2015 | 477 | 0.150 |
Why?
| | Metallothionein | 8 | 1994 | 25 | 0.140 |
Why?
| | Sequence Analysis, DNA | 4 | 2015 | 780 | 0.140 |
Why?
| | Ribosomes | 3 | 2005 | 193 | 0.140 |
Why?
| | Sepsis | 2 | 2016 | 671 | 0.140 |
Why?
| | Streptococcus pneumoniae | 2 | 2012 | 190 | 0.140 |
Why?
| | Streptococcal Infections | 2 | 2012 | 178 | 0.130 |
Why?
| | Quinazolines | 1 | 1999 | 266 | 0.130 |
Why?
| | Tick Infestations | 1 | 2017 | 5 | 0.130 |
Why?
| | RNA, Bacterial | 6 | 2013 | 182 | 0.130 |
Why?
| | Cell Fusion | 2 | 1994 | 48 | 0.130 |
Why?
| | Evolution, Molecular | 3 | 2012 | 502 | 0.130 |
Why?
| | HIV Envelope Protein gp120 | 2 | 1994 | 55 | 0.130 |
Why?
| | Pneumonia, Bacterial | 2 | 2015 | 115 | 0.130 |
Why?
| | Communicable Disease Control | 2 | 2008 | 86 | 0.130 |
Why?
| | Healthcare Disparities | 1 | 2024 | 740 | 0.130 |
Why?
| | Glossitis, Benign Migratory | 2 | 2013 | 5 | 0.120 |
Why?
| | Ticks | 3 | 2012 | 30 | 0.120 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2012 | 2223 | 0.120 |
Why?
| | Structure-Activity Relationship | 5 | 1999 | 567 | 0.120 |
Why?
| | Specimen Handling | 2 | 2015 | 183 | 0.120 |
Why?
| | Klebsiella Infections | 2 | 2010 | 26 | 0.120 |
Why?
| | Blood-Borne Pathogens | 1 | 2015 | 7 | 0.120 |
Why?
| | Drug Evaluation, Preclinical | 4 | 1997 | 196 | 0.110 |
Why?
| | Nucleosides | 1 | 1995 | 25 | 0.110 |
Why?
| | Phylogeny | 3 | 2015 | 924 | 0.110 |
Why?
| | Models, Biological | 1 | 2003 | 1772 | 0.110 |
Why?
| | Models, Chemical | 2 | 1996 | 251 | 0.110 |
Why?
| | Cluster Analysis | 3 | 2012 | 502 | 0.110 |
Why?
| | Chemistry, Pharmaceutical | 2 | 1995 | 112 | 0.110 |
Why?
| | Enterobacteriaceae Infections | 1 | 2015 | 43 | 0.110 |
Why?
| | Species Specificity | 4 | 2012 | 547 | 0.110 |
Why?
| | Simplexvirus | 2 | 1993 | 82 | 0.110 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2015 | 98 | 0.110 |
Why?
| | Streptococcus pyogenes | 2 | 2009 | 41 | 0.110 |
Why?
| | Babesia microti | 1 | 2014 | 1 | 0.110 |
Why?
| | Health Care Reform | 1 | 2015 | 109 | 0.110 |
Why?
| | Conserved Sequence | 2 | 2005 | 244 | 0.100 |
Why?
| | Genes, Fungal | 4 | 1994 | 55 | 0.100 |
Why?
| | Carbapenems | 2 | 2013 | 28 | 0.100 |
Why?
| | Statistics as Topic | 2 | 2012 | 285 | 0.100 |
Why?
| | Hand, Foot and Mouth Disease | 1 | 2013 | 3 | 0.100 |
Why?
| | Serologic Tests | 1 | 2013 | 54 | 0.100 |
Why?
| | Multilocus Sequence Typing | 1 | 2013 | 16 | 0.100 |
Why?
| | Mastitis, Bovine | 1 | 2013 | 2 | 0.100 |
Why?
| | Europe | 4 | 2016 | 426 | 0.100 |
Why?
| | Aza Compounds | 1 | 2013 | 12 | 0.100 |
Why?
| | Povidone-Iodine | 1 | 2013 | 12 | 0.100 |
Why?
| | Venous Thrombosis | 1 | 2015 | 199 | 0.100 |
Why?
| | Mycology | 1 | 2013 | 5 | 0.100 |
Why?
| | Neoplasms | 1 | 2009 | 2946 | 0.100 |
Why?
| | Enterovirus | 1 | 2013 | 83 | 0.090 |
Why?
| | Pulmonary Embolism | 1 | 2015 | 246 | 0.090 |
Why?
| | Bacterial Proteins | 5 | 2011 | 976 | 0.090 |
Why?
| | Streptococcus intermedius | 1 | 2012 | 1 | 0.090 |
Why?
| | Genes | 3 | 1989 | 230 | 0.090 |
Why?
| | DNA | 7 | 2010 | 1444 | 0.090 |
Why?
| | Fusion Proteins, gag-pol | 1 | 1992 | 2 | 0.090 |
Why?
| | Frameshift Mutation | 1 | 1992 | 32 | 0.090 |
Why?
| | Dirofilariasis | 1 | 2012 | 1 | 0.090 |
Why?
| | Ixodidae | 1 | 2012 | 7 | 0.090 |
Why?
| | Infection Control | 1 | 2014 | 174 | 0.090 |
Why?
| | Eye Infections, Bacterial | 1 | 2013 | 46 | 0.090 |
Why?
| | False Negative Reactions | 1 | 2012 | 61 | 0.090 |
Why?
| | Emergency Service, Hospital | 2 | 2023 | 2416 | 0.090 |
Why?
| | Milk | 1 | 2013 | 119 | 0.090 |
Why?
| | Francisella tularensis | 1 | 2012 | 33 | 0.090 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2013 | 72 | 0.090 |
Why?
| | Limit of Detection | 1 | 2012 | 92 | 0.090 |
Why?
| | Diarrhea | 1 | 2013 | 193 | 0.090 |
Why?
| | Enzyme Inhibitors | 1 | 1995 | 822 | 0.090 |
Why?
| | Antitubercular Agents | 2 | 2011 | 211 | 0.090 |
Why?
| | RNA, Antisense | 1 | 1991 | 18 | 0.090 |
Why?
| | Virus Replication | 5 | 2005 | 521 | 0.090 |
Why?
| | Prostheses and Implants | 1 | 2013 | 137 | 0.090 |
Why?
| | Research Report | 1 | 2012 | 89 | 0.090 |
Why?
| | RNA Caps | 1 | 1991 | 32 | 0.090 |
Why?
| | Biological Assay | 1 | 2012 | 134 | 0.090 |
Why?
| | Quinolines | 1 | 2013 | 192 | 0.090 |
Why?
| | HIV Long Terminal Repeat | 1 | 1991 | 12 | 0.090 |
Why?
| | Xenotropic murine leukemia virus-related virus | 1 | 2011 | 1 | 0.080 |
Why?
| | Serotyping | 2 | 2008 | 31 | 0.080 |
Why?
| | Molecular Typing | 1 | 2011 | 21 | 0.080 |
Why?
| | Fatigue Syndrome, Chronic | 1 | 2011 | 19 | 0.080 |
Why?
| | Nucleic Acids | 1 | 2012 | 72 | 0.080 |
Why?
| | Hospitals, Military | 2 | 2008 | 29 | 0.080 |
Why?
| | Thermodynamics | 6 | 2002 | 420 | 0.080 |
Why?
| | Signal Transduction | 1 | 2004 | 5272 | 0.080 |
Why?
| | Mycoplasma | 1 | 2010 | 5 | 0.080 |
Why?
| | Nasopharynx | 1 | 2011 | 73 | 0.080 |
Why?
| | Helicobacter | 1 | 2010 | 3 | 0.080 |
Why?
| | Dog Diseases | 1 | 2012 | 141 | 0.080 |
Why?
| | Disease Vectors | 1 | 2010 | 15 | 0.080 |
Why?
| | Pyoderma Gangrenosum | 1 | 2010 | 8 | 0.080 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2010 | 39 | 0.080 |
Why?
| | Enterobacteriaceae | 1 | 2010 | 44 | 0.080 |
Why?
| | Helicobacter Infections | 1 | 2010 | 30 | 0.080 |
Why?
| | Mutation | 5 | 1996 | 4130 | 0.080 |
Why?
| | Flavivirus | 1 | 2010 | 19 | 0.080 |
Why?
| | Ehrlichia | 1 | 2009 | 4 | 0.080 |
Why?
| | Agammaglobulinemia | 1 | 2010 | 36 | 0.080 |
Why?
| | Feces | 1 | 2013 | 500 | 0.080 |
Why?
| | Ehrlichiosis | 1 | 2009 | 4 | 0.080 |
Why?
| | Male | 20 | 2016 | 73950 | 0.080 |
Why?
| | beta-Lactamases | 1 | 2010 | 54 | 0.080 |
Why?
| | Mycobacterium | 1 | 2010 | 101 | 0.080 |
Why?
| | Orthopoxvirus | 1 | 2009 | 4 | 0.080 |
Why?
| | Military Personnel | 3 | 2006 | 749 | 0.070 |
Why?
| | Medicare | 1 | 2015 | 915 | 0.070 |
Why?
| | Middle Aged | 14 | 2016 | 36821 | 0.070 |
Why?
| | Protozoan Infections | 2 | 2008 | 11 | 0.070 |
Why?
| | Female | 20 | 2016 | 80076 | 0.070 |
Why?
| | Time Factors | 5 | 2015 | 7173 | 0.070 |
Why?
| | Nucleic Acid Hybridization | 6 | 1996 | 188 | 0.070 |
Why?
| | Peptide Library | 3 | 1999 | 91 | 0.070 |
Why?
| | Yeasts | 2 | 2013 | 53 | 0.070 |
Why?
| | Metals | 2 | 1986 | 138 | 0.070 |
Why?
| | Monte Carlo Method | 4 | 1997 | 148 | 0.070 |
Why?
| | Eukaryota | 2 | 2008 | 56 | 0.070 |
Why?
| | Disulfides | 1 | 1989 | 94 | 0.070 |
Why?
| | Young Adult | 7 | 2016 | 14437 | 0.070 |
Why?
| | Thalassemia | 1 | 2008 | 6 | 0.070 |
Why?
| | Porifera | 1 | 2008 | 8 | 0.070 |
Why?
| | Marine Toxins | 1 | 2008 | 12 | 0.070 |
Why?
| | Adult | 15 | 2016 | 41405 | 0.070 |
Why?
| | Chlamydiales | 1 | 2007 | 1 | 0.070 |
Why?
| | Campylobacter | 1 | 2008 | 10 | 0.070 |
Why?
| | Receptor, IGF Type 1 | 1 | 2008 | 64 | 0.070 |
Why?
| | Computational Biology | 2 | 2002 | 677 | 0.070 |
Why?
| | United States | 6 | 2018 | 16313 | 0.070 |
Why?
| | Pneumococcal Infections | 1 | 2008 | 106 | 0.070 |
Why?
| | Mycobacterium tuberculosis | 1 | 2011 | 324 | 0.060 |
Why?
| | Warfare | 1 | 2008 | 100 | 0.060 |
Why?
| | Adolescent | 11 | 2016 | 22825 | 0.060 |
Why?
| | Aged | 9 | 2016 | 26514 | 0.060 |
Why?
| | Genome, Bacterial | 2 | 2012 | 123 | 0.060 |
Why?
| | Infant | 5 | 2013 | 10194 | 0.060 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2013 | 512 | 0.060 |
Why?
| | Adenovirus Infections, Human | 1 | 2006 | 15 | 0.060 |
Why?
| | Adenoviruses, Human | 1 | 2006 | 26 | 0.060 |
Why?
| | Cancer Vaccines | 1 | 2008 | 164 | 0.060 |
Why?
| | Quinolones | 1 | 2009 | 206 | 0.060 |
Why?
| | Regulatory Sequences, Nucleic Acid | 2 | 2001 | 93 | 0.060 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2006 | 77 | 0.060 |
Why?
| | Pharmaceutical Preparations | 1 | 2008 | 172 | 0.060 |
Why?
| | Neuropeptides | 1 | 2006 | 75 | 0.060 |
Why?
| | RNA Interference | 1 | 2008 | 477 | 0.060 |
Why?
| | Plasmids | 5 | 1992 | 373 | 0.060 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2005 | 18 | 0.060 |
Why?
| | Child, Preschool | 5 | 2013 | 12016 | 0.060 |
Why?
| | Phospholipases A | 2 | 1996 | 97 | 0.060 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2008 | 232 | 0.060 |
Why?
| | Forensic Sciences | 1 | 2005 | 4 | 0.060 |
Why?
| | Prevalence | 4 | 2014 | 2889 | 0.060 |
Why?
| | Mice | 9 | 2017 | 18491 | 0.060 |
Why?
| | Huntington Disease | 1 | 2006 | 61 | 0.060 |
Why?
| | DNA Fingerprinting | 3 | 2010 | 28 | 0.060 |
Why?
| | Binding Sites | 4 | 2005 | 1319 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 5 | 1992 | 669 | 0.060 |
Why?
| | Early Diagnosis | 2 | 2016 | 254 | 0.050 |
Why?
| | Aged, 80 and over | 6 | 2016 | 8430 | 0.050 |
Why?
| | Genetic Variation | 1 | 2010 | 995 | 0.050 |
Why?
| | Bacillus anthracis | 1 | 2004 | 13 | 0.050 |
Why?
| | Prospective Studies | 5 | 2016 | 8164 | 0.050 |
Why?
| | Genetic Engineering | 1 | 2005 | 89 | 0.050 |
Why?
| | Genotyping Techniques | 2 | 2015 | 72 | 0.050 |
Why?
| | Benzimidazoles | 1 | 2005 | 190 | 0.050 |
Why?
| | Protein Precursors | 2 | 1999 | 136 | 0.050 |
Why?
| | Kinetics | 9 | 1999 | 1569 | 0.050 |
Why?
| | DNA, Mitochondrial | 1 | 2005 | 212 | 0.050 |
Why?
| | Hepacivirus | 1 | 2005 | 243 | 0.050 |
Why?
| | Videotape Recording | 1 | 2023 | 37 | 0.050 |
Why?
| | Maze Learning | 1 | 2004 | 105 | 0.050 |
Why?
| | RNA, Ribosomal | 2 | 2001 | 168 | 0.050 |
Why?
| | Amino Acid Sequence | 5 | 1992 | 2134 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 459 | 0.050 |
Why?
| | Chemistry | 1 | 2003 | 41 | 0.050 |
Why?
| | Chemical Phenomena | 1 | 2003 | 77 | 0.050 |
Why?
| | rev Gene Products, Human Immunodeficiency Virus | 1 | 2002 | 6 | 0.050 |
Why?
| | Polyethylene Glycols | 1 | 2008 | 649 | 0.050 |
Why?
| | Regulatory Sequences, Ribonucleic Acid | 1 | 2002 | 18 | 0.050 |
Why?
| | Child | 6 | 2013 | 22979 | 0.050 |
Why?
| | Genomics | 1 | 2008 | 839 | 0.050 |
Why?
| | Recombinant Proteins | 4 | 2006 | 1371 | 0.050 |
Why?
| | Writing | 1 | 2023 | 101 | 0.040 |
Why?
| | Animals, Genetically Modified | 1 | 2003 | 248 | 0.040 |
Why?
| | Gene Products, tat | 2 | 1992 | 22 | 0.040 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 2 | 1992 | 25 | 0.040 |
Why?
| | Antibodies, Bacterial | 2 | 2013 | 148 | 0.040 |
Why?
| | Rho Factor | 1 | 2001 | 4 | 0.040 |
Why?
| | Primates | 1 | 2002 | 133 | 0.040 |
Why?
| | Cerebrospinal Fluid | 2 | 2012 | 88 | 0.040 |
Why?
| | Minisatellite Repeats | 2 | 2012 | 36 | 0.040 |
Why?
| | Educational Status | 1 | 2023 | 475 | 0.040 |
Why?
| | Cell Line | 3 | 2005 | 2832 | 0.040 |
Why?
| | Ohio | 2 | 2012 | 146 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2008 | 1514 | 0.040 |
Why?
| | Models, Molecular | 1 | 2005 | 1606 | 0.040 |
Why?
| | RNA, Transfer | 1 | 2001 | 143 | 0.040 |
Why?
| | Encephalitis Viruses, Tick-Borne | 2 | 2010 | 8 | 0.040 |
Why?
| | Reproducibility of Results | 3 | 2013 | 3448 | 0.040 |
Why?
| | Point Mutation | 2 | 2009 | 245 | 0.040 |
Why?
| | RNA, Ribosomal, 18S | 1 | 1999 | 21 | 0.040 |
Why?
| | Mice, Inbred ICR | 1 | 1999 | 113 | 0.040 |
Why?
| | Enterococcus faecalis | 1 | 1999 | 29 | 0.040 |
Why?
| | Forecasting | 1 | 2001 | 391 | 0.040 |
Why?
| | Splanchnic Circulation | 1 | 1999 | 12 | 0.040 |
Why?
| | Extracorporeal Circulation | 1 | 1999 | 15 | 0.040 |
Why?
| | Critical Illness | 2 | 2016 | 907 | 0.040 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 2 | 2009 | 22 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 1999 | 125 | 0.040 |
Why?
| | Calcitonin | 1 | 1999 | 27 | 0.040 |
Why?
| | Protein Biosynthesis | 2 | 1999 | 452 | 0.030 |
Why?
| | Genetic Markers | 2 | 2012 | 338 | 0.030 |
Why?
| | Mutation, Missense | 2 | 2011 | 337 | 0.030 |
Why?
| | Artiodactyla | 1 | 2017 | 2 | 0.030 |
Why?
| | Czech Republic | 1 | 2017 | 4 | 0.030 |
Why?
| | RNA, Messenger | 5 | 1994 | 2812 | 0.030 |
Why?
| | Sus scrofa | 1 | 2017 | 66 | 0.030 |
Why?
| | Deer | 1 | 2017 | 52 | 0.030 |
Why?
| | Arvicolinae | 1 | 2017 | 32 | 0.030 |
Why?
| | Auranofin | 2 | 1987 | 6 | 0.030 |
Why?
| | Birds | 1 | 2017 | 87 | 0.030 |
Why?
| | GTP-Binding Proteins | 2 | 1994 | 153 | 0.030 |
Why?
| | HeLa Cells | 3 | 1993 | 633 | 0.030 |
Why?
| | Risk Assessment | 2 | 2016 | 3784 | 0.030 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 1996 | 73 | 0.030 |
Why?
| | Sciuridae | 1 | 2017 | 152 | 0.030 |
Why?
| | Anxiety | 1 | 2004 | 1149 | 0.030 |
Why?
| | Receptors, Leukotriene B4 | 1 | 1995 | 7 | 0.030 |
Why?
| | Endopeptidases | 3 | 1994 | 80 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 1995 | 36 | 0.030 |
Why?
| | Binding, Competitive | 1 | 1995 | 185 | 0.030 |
Why?
| | Gram-Positive Bacteria | 1 | 2015 | 48 | 0.030 |
Why?
| | Body Fluids | 1 | 2015 | 71 | 0.030 |
Why?
| | Esters | 1 | 1995 | 71 | 0.030 |
Why?
| | Gram-Negative Bacteria | 1 | 2015 | 80 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 1993 | 256 | 0.030 |
Why?
| | Cytopathogenic Effect, Viral | 1 | 1994 | 17 | 0.030 |
Why?
| | Biotechnology | 1 | 1995 | 45 | 0.030 |
Why?
| | Arthropod Vectors | 1 | 2014 | 7 | 0.030 |
Why?
| | Adenylyl Cyclases | 1 | 1994 | 60 | 0.030 |
Why?
| | Macromolecular Substances | 1 | 1995 | 216 | 0.030 |
Why?
| | Automation, Laboratory | 1 | 2014 | 8 | 0.030 |
Why?
| | Zidovudine | 1 | 1994 | 77 | 0.030 |
Why?
| | Mupirocin | 1 | 2014 | 7 | 0.030 |
Why?
| | Germany | 1 | 2014 | 140 | 0.030 |
Why?
| | Methicillin Resistance | 1 | 2014 | 17 | 0.030 |
Why?
| | Maryland | 1 | 2014 | 67 | 0.030 |
Why?
| | Fungal Proteins | 1 | 1994 | 143 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 1998 | 2030 | 0.020 |
Why?
| | Tritium | 1 | 1993 | 67 | 0.020 |
Why?
| | Amplified Fragment Length Polymorphism Analysis | 1 | 2013 | 1 | 0.020 |
Why?
| | Nose | 1 | 2014 | 68 | 0.020 |
Why?
| | Bangladesh | 1 | 2013 | 64 | 0.020 |
Why?
| | Arizona | 1 | 2013 | 81 | 0.020 |
Why?
| | Survival Analysis | 1 | 2016 | 1386 | 0.020 |
Why?
| | Africa | 1 | 2013 | 119 | 0.020 |
Why?
| | Fluoroquinolones | 1 | 2013 | 44 | 0.020 |
Why?
| | Cattle | 2 | 2013 | 948 | 0.020 |
Why?
| | Anti-Infective Agents, Local | 1 | 2013 | 41 | 0.020 |
Why?
| | Gene Library | 1 | 1993 | 122 | 0.020 |
Why?
| | Virulence | 1 | 1994 | 286 | 0.020 |
Why?
| | Brain Abscess | 1 | 2012 | 10 | 0.020 |
Why?
| | Endophthalmitis | 1 | 2013 | 46 | 0.020 |
Why?
| | Corneal Diseases | 1 | 2013 | 48 | 0.020 |
Why?
| | Nymph | 1 | 2012 | 4 | 0.020 |
Why?
| | Rabbits | 2 | 2009 | 654 | 0.020 |
Why?
| | Cloning, Molecular | 3 | 1989 | 539 | 0.020 |
Why?
| | Reticulocytes | 2 | 1989 | 17 | 0.020 |
Why?
| | Genes, ras | 1 | 1992 | 96 | 0.020 |
Why?
| | Ovum | 1 | 2012 | 30 | 0.020 |
Why?
| | Tularemia | 1 | 2012 | 30 | 0.020 |
Why?
| | Prosthesis-Related Infections | 1 | 2013 | 99 | 0.020 |
Why?
| | Bacterial Outer Membrane Proteins | 2 | 2010 | 62 | 0.020 |
Why?
| | DNA, Ribosomal | 1 | 2012 | 84 | 0.020 |
Why?
| | Gene Expression Regulation, Viral | 1 | 1992 | 93 | 0.020 |
Why?
| | Iron | 2 | 2002 | 361 | 0.020 |
Why?
| | Microbial Viability | 1 | 2012 | 83 | 0.020 |
Why?
| | Ribonuclease H | 1 | 1991 | 12 | 0.020 |
Why?
| | Nucleic Acid Denaturation | 1 | 1991 | 32 | 0.020 |
Why?
| | Antibiotic Prophylaxis | 1 | 2013 | 135 | 0.020 |
Why?
| | Ligases | 2 | 1989 | 38 | 0.020 |
Why?
| | Adenosine | 1 | 1993 | 255 | 0.020 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 1989 | 627 | 0.020 |
Why?
| | Larva | 1 | 2012 | 242 | 0.020 |
Why?
| | Parainfluenza Virus 2, Human | 1 | 2011 | 3 | 0.020 |
Why?
| | Parainfluenza Virus 3, Human | 1 | 2011 | 5 | 0.020 |
Why?
| | Cell Cycle | 1 | 1994 | 600 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 332 | 0.020 |
Why?
| | Georgia (Republic) | 1 | 2010 | 4 | 0.020 |
Why?
| | Endemic Diseases | 1 | 2011 | 33 | 0.020 |
Why?
| | Influenza B virus | 1 | 2011 | 47 | 0.020 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2011 | 33 | 0.020 |
Why?
| | New York City | 1 | 2010 | 87 | 0.020 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2011 | 58 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 1991 | 145 | 0.020 |
Why?
| | Pregnancy | 1 | 2004 | 7274 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1994 | 698 | 0.020 |
Why?
| | Dogs | 1 | 2012 | 518 | 0.020 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 251 | 0.020 |
Why?
| | Anti-HIV Agents | 1 | 1998 | 919 | 0.020 |
Why?
| | Phenotype | 2 | 2009 | 3216 | 0.020 |
Why?
| | Rifampin | 1 | 2010 | 79 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2011 | 247 | 0.020 |
Why?
| | Liver | 1 | 1999 | 1916 | 0.020 |
Why?
| | Flavivirus Infections | 1 | 2010 | 9 | 0.020 |
Why?
| | China | 1 | 2011 | 278 | 0.020 |
Why?
| | Isoniazid | 1 | 2010 | 70 | 0.020 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2010 | 26 | 0.020 |
Why?
| | Culicidae | 1 | 2010 | 33 | 0.020 |
Why?
| | Rickettsia rickettsii | 1 | 2009 | 1 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2013 | 1046 | 0.020 |
Why?
| | Water | 1 | 1993 | 452 | 0.020 |
Why?
| | DNA, Protozoan | 1 | 2010 | 32 | 0.020 |
Why?
| | Neisseria meningitidis | 1 | 2009 | 23 | 0.020 |
Why?
| | West Nile virus | 1 | 2010 | 41 | 0.020 |
Why?
| | RNA, Protozoan | 1 | 2010 | 60 | 0.020 |
Why?
| | South Africa | 1 | 2010 | 269 | 0.020 |
Why?
| | Geography | 1 | 2010 | 187 | 0.020 |
Why?
| | Critical Care | 1 | 2015 | 705 | 0.020 |
Why?
| | Antigens, Bacterial | 1 | 2010 | 126 | 0.020 |
Why?
| | DNA Topoisomerase IV | 1 | 2009 | 1 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2009 | 158 | 0.020 |
Why?
| | Dengue Virus | 1 | 2010 | 62 | 0.020 |
Why?
| | DNA Gyrase | 1 | 2009 | 8 | 0.020 |
Why?
| | Transcriptional Activation | 1 | 1991 | 372 | 0.020 |
Why?
| | North America | 1 | 2010 | 307 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2015 | 928 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2013 | 6543 | 0.020 |
Why?
| | Cystine | 1 | 1989 | 17 | 0.020 |
Why?
| | Genetic Vectors | 2 | 1988 | 335 | 0.020 |
Why?
| | Bacterial Toxins | 1 | 2009 | 109 | 0.020 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1989 | 58 | 0.020 |
Why?
| | Genetic Loci | 1 | 2010 | 272 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1518 | 0.020 |
Why?
| | Molecular Weight | 4 | 1990 | 313 | 0.020 |
Why?
| | Cells, Cultured | 2 | 1994 | 4169 | 0.020 |
Why?
| | Forensic Medicine | 1 | 2008 | 19 | 0.020 |
Why?
| | Government Agencies | 1 | 2008 | 14 | 0.020 |
Why?
| | Multigene Family | 1 | 1989 | 210 | 0.020 |
Why?
| | Temperature | 1 | 1991 | 638 | 0.020 |
Why?
| | Protein Binding | 1 | 1994 | 2249 | 0.020 |
Why?
| | Campylobacter coli | 1 | 2008 | 1 | 0.020 |
Why?
| | Campylobacter jejuni | 1 | 2008 | 16 | 0.020 |
Why?
| | Acute Disease | 1 | 2011 | 1049 | 0.020 |
Why?
| | Viral Load | 1 | 2010 | 528 | 0.020 |
Why?
| | Prognosis | 1 | 2016 | 4383 | 0.020 |
Why?
| | Gene Expression | 1 | 1992 | 1481 | 0.020 |
Why?
| | Promoter Regions, Genetic | 2 | 1994 | 1253 | 0.020 |
Why?
| | User-Computer Interface | 1 | 2008 | 165 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1994 | 1162 | 0.020 |
Why?
| | Phosphines | 1 | 1986 | 18 | 0.020 |
Why?
| | Orexins | 1 | 2006 | 6 | 0.020 |
Why?
| | Huntingtin Protein | 1 | 2006 | 13 | 0.020 |
Why?
| | Sequence Homology | 1 | 2006 | 43 | 0.020 |
Why?
| | Enterobactin | 1 | 1986 | 8 | 0.020 |
Why?
| | Pseudomonas aeruginosa | 1 | 2009 | 397 | 0.020 |
Why?
| | Oligopeptides | 1 | 1988 | 267 | 0.010 |
Why?
| | DNA Restriction Enzymes | 1 | 2005 | 53 | 0.010 |
Why?
| | Protein Conformation | 1 | 1989 | 943 | 0.010 |
Why?
| | Serine | 1 | 1986 | 143 | 0.010 |
Why?
| | Decision Making | 1 | 2013 | 994 | 0.010 |
Why?
| | Databases, Nucleic Acid | 1 | 2005 | 39 | 0.010 |
Why?
| | Organometallic Compounds | 1 | 1986 | 113 | 0.010 |
Why?
| | Housing | 1 | 2006 | 142 | 0.010 |
Why?
| | Automation | 1 | 2005 | 104 | 0.010 |
Why?
| | Molecular Structure | 2 | 1996 | 488 | 0.010 |
Why?
| | Tandem Repeat Sequences | 1 | 2004 | 23 | 0.010 |
Why?
| | Fourier Analysis | 1 | 2004 | 42 | 0.010 |
Why?
| | Ovary | 1 | 1986 | 236 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 6164 | 0.010 |
Why?
| | Receptors, Cell Surface | 1 | 1986 | 373 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 2133 | 0.010 |
Why?
| | Fibroblasts | 1 | 1989 | 1039 | 0.010 |
Why?
| | Signal Recognition Particle | 1 | 2002 | 9 | 0.010 |
Why?
| | Genetic Complementation Test | 2 | 1994 | 72 | 0.010 |
Why?
| | Ferritins | 1 | 2002 | 70 | 0.010 |
Why?
| | Nerve Tissue Proteins | 1 | 2006 | 597 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2012 | 5476 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 2006 | 687 | 0.010 |
Why?
| | RNA, Ribosomal, 23S | 1 | 2001 | 12 | 0.010 |
Why?
| | Alleles | 1 | 2004 | 909 | 0.010 |
Why?
| | Copper | 2 | 1994 | 122 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 2006 | 745 | 0.010 |
Why?
| | 3' Untranslated Regions | 1 | 2001 | 149 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2006 | 2197 | 0.010 |
Why?
| | Pilot Projects | 1 | 2005 | 1912 | 0.010 |
Why?
| | Aminoglycosides | 1 | 1999 | 30 | 0.010 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 1999 | 40 | 0.010 |
Why?
| | Risk Factors | 1 | 2014 | 11017 | 0.010 |
Why?
| | Protein Processing, Post-Translational | 2 | 1994 | 480 | 0.010 |
Why?
| | Ubiquitin-Activating Enzymes | 2 | 1989 | 20 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2006 | 3660 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2006 | 3565 | 0.010 |
Why?
| | Postoperative Period | 1 | 1999 | 351 | 0.010 |
Why?
| | Mice, SCID | 1 | 1998 | 369 | 0.010 |
Why?
| | Ligands | 1 | 1999 | 675 | 0.010 |
Why?
| | Coronary Artery Bypass | 1 | 1999 | 269 | 0.010 |
Why?
| | Ubiquitin-Protein Ligases | 2 | 1989 | 199 | 0.010 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 237 | 0.010 |
Why?
| | Phospholipases A2 | 1 | 1996 | 79 | 0.010 |
Why?
| | Cadmium | 2 | 1987 | 68 | 0.010 |
Why?
| | Cricetinae | 2 | 1987 | 305 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1996 | 164 | 0.010 |
Why?
| | Gold | 2 | 1986 | 116 | 0.010 |
Why?
| | Transducin | 1 | 1994 | 42 | 0.010 |
Why?
| | Biomarkers | 1 | 2006 | 4351 | 0.010 |
Why?
| | RNA, Fungal | 1 | 1994 | 67 | 0.010 |
Why?
| | Genes, Dominant | 1 | 1994 | 100 | 0.010 |
Why?
| | Mercaptoethanol | 1 | 1993 | 8 | 0.010 |
Why?
| | Methods | 1 | 1993 | 68 | 0.010 |
Why?
| | Cell Survival | 2 | 1987 | 1111 | 0.010 |
Why?
| | Circular Dichroism | 1 | 1993 | 152 | 0.010 |
Why?
| | Bovine papillomavirus 1 | 1 | 1992 | 1 | 0.010 |
Why?
| | Luciferases | 1 | 1992 | 155 | 0.010 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1992 | 132 | 0.010 |
Why?
| | Codon | 1 | 1992 | 92 | 0.010 |
Why?
| | Lysine | 1 | 1994 | 305 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1993 | 891 | 0.010 |
Why?
| | Cell Adhesion Molecules | 1 | 1992 | 182 | 0.010 |
Why?
| | Cytokines | 1 | 1999 | 2086 | 0.010 |
Why?
| | Cell Membrane | 1 | 1994 | 711 | 0.010 |
Why?
| | Chromosome Deletion | 1 | 1990 | 127 | 0.000 |
Why?
| | T-Lymphocytes | 1 | 1998 | 2017 | 0.000 |
Why?
| | Butyric Acid | 1 | 1989 | 6 | 0.000 |
Why?
| | Phorbol 12,13-Dibutyrate | 1 | 1989 | 8 | 0.000 |
Why?
| | Electrophoresis | 1 | 1989 | 31 | 0.000 |
Why?
| | Chromatography, Ion Exchange | 1 | 1989 | 57 | 0.000 |
Why?
| | Copper Sulfate | 1 | 1988 | 8 | 0.000 |
Why?
| | Methylation | 1 | 1989 | 242 | 0.000 |
Why?
| | Substrate Specificity | 1 | 1989 | 387 | 0.000 |
Why?
| | Butyrates | 1 | 1989 | 66 | 0.000 |
Why?
| | Membrane Proteins | 1 | 1994 | 1171 | 0.000 |
Why?
| | Retrospective Studies | 1 | 2006 | 17560 | 0.000 |
Why?
| | Hydrolysis | 1 | 1988 | 197 | 0.000 |
Why?
| | Disease Models, Animal | 1 | 1998 | 4604 | 0.000 |
Why?
| | Organogold Compounds | 1 | 1986 | 5 | 0.000 |
Why?
| | Dexamethasone | 1 | 1989 | 368 | 0.000 |
Why?
| | Cell Compartmentation | 1 | 1986 | 52 | 0.000 |
Why?
| | Cricetulus | 1 | 1986 | 118 | 0.000 |
Why?
| | Osmolar Concentration | 1 | 1986 | 168 | 0.000 |
Why?
| | Drug Resistance | 1 | 1987 | 145 | 0.000 |
Why?
| | Spectrum Analysis | 1 | 1986 | 85 | 0.000 |
Why?
| | Albumins | 1 | 1986 | 119 | 0.000 |
Why?
| | Tissue Distribution | 1 | 1986 | 335 | 0.000 |
Why?
| | Adenosine Triphosphate | 1 | 1988 | 500 | 0.000 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1986 | 536 | 0.000 |
Why?
| | Sulfhydryl Compounds | 1 | 1986 | 189 | 0.000 |
Why?
| | Amino Acids | 1 | 1987 | 519 | 0.000 |
Why?
| | Polymers | 1 | 1987 | 486 | 0.000 |
Why?
| | Zinc | 1 | 1986 | 309 | 0.000 |
Why?
| | Carrier Proteins | 1 | 1986 | 731 | 0.000 |
Why?
| | Proteins | 1 | 1986 | 1024 | 0.000 |
Why?
|
|
Ecker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|